The central question about gene editing for cholesterol was never whether it works. It was whether it lasts. Investigators have now followed patients for a full year after a single infusion and reported that the effect held.
Among participants who received the highest dose of the experimental CRISPR-Cas9 therapy CTX310, LDL cholesterol was 52.5 percent below baseline, and triglycerides were 47.8 percent lower at 12 months. No serious adverse events related to the therapy were recorded during that year. The results were presented at the European Society of Cardiology Congress and published simultaneously in the New England Journal of Medicine, according to Cleveland Clinic, whose cardiologists led the study.
